Is there utility in testing IgA-endomysial antibodies in patients with weak-positive or equivocal IgA-tissue transglutaminase antibodies in the diagnosis of coeliac disease? A critique of current NICE guidance (NG20)​Samuel D Brown, Jacqueline Hitchins, Newton ACS Wong, Amy Hayes, Alice Ogden, Adrian Heaps, Philip Bright1Clinical Biochemistry, Royal Sussex County Hospital, Brighton, UK2Clinical Biochemistry, 1984University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK3Department of Cellular Pathology, 1982North Bristol NHS Trust, Bristol, UK4Department of Immunology & Immunogenetics, 1982North Bristol NHS Trust, Bristol, UKon June 11, 2025 at 9:03 am

by

Annals of Clinical Biochemistry, Ahead of Print.
BackgroundCurrent coeliac disease (CD) NICE guidelines recommend testing IgA-endomysial antibodies (EMA) following a weak-positive IgA-tissue transglutaminase antibody (tTGA). Outside of patients with very high IgA-tTGA results, a positive IgA-EMA …

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

deneme bonusu veren siteler - canlı bahis siteleri - casino siteleri casino siteleri deneme bonusu veren siteler canlı casino siteleri error code: 520